- Home
- SD vs PHAT Comparison
SD vs PHAT Comparison
Compare SD & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SD
- PHAT
- Stock Information
- Founded
- SD 2006
- PHAT 2018
- Country
- SD United States
- PHAT United States
- Employees
- SD N/A
- PHAT N/A
- Industry
- SD Oil & Gas Production
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- SD Energy
- PHAT Health Care
- Exchange
- SD Nasdaq
- PHAT Nasdaq
- Market Cap
- SD 465.2M
- PHAT 415.7M
- IPO Year
- SD 2007
- PHAT 2019
- Fundamental
- Price
- SD $11.19
- PHAT $4.37
- Analyst Decision
- SD
- PHAT Strong Buy
- Analyst Count
- SD 0
- PHAT 4
- Target Price
- SD N/A
- PHAT $23.00
- AVG Volume (30 Days)
- SD 303.1K
- PHAT 1.1M
- Earning Date
- SD 03-10-2025
- PHAT 03-06-2025
- Dividend Yield
- SD 3.80%
- PHAT N/A
- EPS Growth
- SD 3.05
- PHAT N/A
- EPS
- SD 1.69
- PHAT N/A
- Revenue
- SD $125,290,000.00
- PHAT $55,252,000.00
- Revenue This Year
- SD $57.83
- PHAT $204.30
- Revenue Next Year
- SD N/A
- PHAT $126.98
- P/E Ratio
- SD $6.86
- PHAT N/A
- Revenue Growth
- SD N/A
- PHAT 8001.47
- 52 Week Low
- SD $10.31
- PHAT $4.33
- 52 Week High
- SD $15.31
- PHAT $19.71
- Technical
- Relative Strength Index (RSI)
- SD 49.53
- PHAT 41.10
- Support Level
- SD $10.74
- PHAT $4.33
- Resistance Level
- SD $11.50
- PHAT $5.25
- Average True Range (ATR)
- SD 0.41
- PHAT 0.59
- MACD
- SD -0.04
- PHAT -0.02
- Stochastic Oscillator
- SD 48.93
- PHAT 23.16
About SD SandRidge Energy Inc.
SandRidge Energy Inc is a United States-based oil and natural gas company. It is engaged in the exploration, development, and production of crude oil, natural gas, and Natural gas liquids. Business activities of the group include Exploration and Production, Drilling and Oil Field Services, and Midstream Gas Services.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.